Ocumension Therapeutics Announces Approval of OT-703 for Real World Study in Hainan Boao

Reuters

2025/05/13

Ocumension <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Approval of OT-703 for Real World Study in Hainan Boao

Ocumension Therapeutics has announced that its product, OT-703 (ILUVIEN®), has been approved for a real-world study in the Boao Lecheng International Medical Tourism Pilot Zone in Hainan Province, China. OT-703 is an injectable, non-biodegradable fluocinolone acetate intravitreal implant designed for the treatment of diabetic macular edema $(DME.AU)$. The implant provides a continuous microdose of corticosteroid fluocinolone acetonide in the eye for up to 36 months. It is the only FDA-approved corticosteroid intraocular implant with a three-year sustained-release period, and it has recently received regulatory approval in Hong Kong. Ocumension holds exclusive rights for its development and commercialization in Greater China, South Korea, and parts of Southeast Asia, following a licensing agreement with Alimera Sciences, Inc.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocumension Therapeutics published the original content used to generate this news brief on May 13, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2535721871"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535721871\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2535721871?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-13 19:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535721871","market":"us","top_or_hot":-1,"title":"Ocumension Therapeutics Announces Approval of OT-703 for Real World Study in Hainan Boao","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Ocumension <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Approval of OT-703 for Real World Study in Hainan Boao\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Ocumension Therapeutics has announced that its product, OT-703 (ILUVIEN®), has been approved for a real-world study in the Boao Lecheng International Medical Tourism Pilot Zone in Hainan Province, China. OT-703 is an injectable, non-biodegradable fluocinolone acetate intravitreal implant designed for the treatment of diabetic macular edema <a href=\"https://laohu8.com/S/DME.AU\">$(DME.AU)$</a>. The implant provides a continuous microdose of corticosteroid fluocinolone acetonide in the eye for up to 36 months. It is the only FDA-approved corticosteroid intraocular implant with a three-year sustained-release period, and it has recently received regulatory approval in Hong Kong. Ocumension holds exclusive rights for its development and commercialization in Greater China, South Korea, and parts of Southeast Asia, following a licensing agreement with Alimera Sciences, Inc.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocumension Therapeutics published the original content used to generate this news brief on May 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocumension Therapeutics Announces Approval of OT-703 for Real World Study in Hainan Boao</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcumension Therapeutics Announces Approval of OT-703 for Real World Study in Hainan Boao\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-13 19:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Ocumension <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Approval of OT-703 for Real World Study in Hainan Boao\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Ocumension Therapeutics has announced that its product, OT-703 (ILUVIEN®), has been approved for a real-world study in the Boao Lecheng International Medical Tourism Pilot Zone in Hainan Province, China. OT-703 is an injectable, non-biodegradable fluocinolone acetate intravitreal implant designed for the treatment of diabetic macular edema <a href=\"https://laohu8.com/S/DME.AU\">$(DME.AU)$</a>. The implant provides a continuous microdose of corticosteroid fluocinolone acetonide in the eye for up to 36 months. It is the only FDA-approved corticosteroid intraocular implant with a three-year sustained-release period, and it has recently received regulatory approval in Hong Kong. Ocumension holds exclusive rights for its development and commercialization in Greater China, South Korea, and parts of Southeast Asia, following a licensing agreement with Alimera Sciences, Inc.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocumension Therapeutics published the original content used to generate this news brief on May 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nNDL83Qq6Y:1","article_id":"2535721871","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535721871","pubTimestamp":1747135496,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Ocumension Therapeutics has announced that its product, OT-703 , has been approved for a real-world study in the Boao Lecheng International Medical Tourism Pilot Zone in Hainan Province, China. OT-703 is an injectable, non-biodegradable fluocinolone acetate intravitreal implant designed for the treatment of diabetic macular edema . The implant provides a continuous microdose of corticosteroid fluocinolone acetonide in the eye for up to 36 months. It is the only FDA-approved corticosteroid intraocular implant with a three-year sustained-release period, and it has recently received regulatory approval in Hong Kong. Ocumension holds exclusive rights for its development and commercialization in Greater China, South Korea, and parts of Southeast Asia, following a licensing agreement with Alimera Sciences, Inc.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generat","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","LU0566484027.USD":"安本美国小盘成长股","LU1559883803.SGD":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H","BK1191":"制药","BK1574":"生物医药B类股","01477":"欧康维视生物-B","ANIP":"ANI Pharmaceuticals, Inc."},"translate_title":"Ocumension Therapeutics宣布批准OT-703在海南博鳌进行真实世界研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANIP":0.9,"01477":0.9},"content_text":"Ocumension Therapeutics Announces Approval of OT-703 for Real World Study in Hainan Boao\n    \n\n        Ocumension Therapeutics has announced that its product, OT-703 (ILUVIEN®), has been approved for a real-world study in the Boao Lecheng International Medical Tourism Pilot Zone in Hainan Province, China. OT-703 is an injectable, non-biodegradable fluocinolone acetate intravitreal implant designed for the treatment of diabetic macular edema $(DME.AU)$. The implant provides a continuous microdose of corticosteroid fluocinolone acetonide in the eye for up to 36 months. It is the only FDA-approved corticosteroid intraocular implant with a three-year sustained-release period, and it has recently received regulatory approval in Hong Kong. Ocumension holds exclusive rights for its development and commercialization in Greater China, South Korea, and parts of Southeast Asia, following a licensing agreement with Alimera Sciences, Inc.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocumension Therapeutics published the original content used to generate this news brief on May 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}